Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer

Ji Hun Kang(Ulsan College), Song Cheol Kim(Ulsan College), Jae Ho Byun(University of Ulsan), Seung Soo Lee(Asan Medical Center), Kyu‐pyo Kim(Ulsan College), Hyoung Jung Kim(University of Ulsan), Changhoon Yoo(Ulsan College), Jin Hee Kim(University of Ulsan), Baek‐Yeol Ryoo(Asan Medical Center)

European Radiology

August 19, 2020

10.1007/s00330-020-07134-8

Cited by 15

Related Papers

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

|Journal of Clinical Oncology|2019|1.8k

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2023|1.1k

Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers

|Proceedings of the National Academy of Sciences|2017|577

A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts

|Gastroenterology|2015|472

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

|The Lancet Oncology|2023|436